Aeglea BioTherapeutics Statistics
Share Statistics
Aeglea BioTherapeutics has 4.05M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 139.69K, so 3.45% of the outstanding
shares have been sold short.
| Short Interest | 139.69K |
| Short % of Shares Out | 3.45% |
| Short % of Float | 3.47% |
| Short Ratio (days to cover) | 4.58 |
Valuation Ratios
The PE ratio is -0.45 and the forward
PE ratio is null.
Aeglea BioTherapeutics's PEG ratio is
0.71.
| PE Ratio | -0.45 |
| Forward PE | n/a |
| PS Ratio | 16.28 |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | 0.71 |
Financial Ratio HistoryEnterprise Valuation
Aeglea BioTherapeutics has an Enterprise Value (EV) of 7.69M.
| EV / Sales | 3.3 |
| EV / EBITDA | -0.09 |
| EV / EBIT | -0.1 |
| EV / FCF | -0.1 |
Financial Position
The company has a current ratio of 4.25,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.25 |
| Quick Ratio | 4.25 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.06 |
| Interest Coverage | -101.29 |
Financial Efficiency
Return on Equity is -166.61% and Return on Invested Capital is -154.08%.
| Return on Equity | -166.61% |
| Return on Assets | -117.81% |
| Return on Invested Capital | -154.08% |
| Revenue Per Employee | $33,753.62 |
| Profits Per Employee | $-1,214,710.14 |
| Employee Count | 69 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -136K |
| Effective Tax Rate | 0.16% |
Stock Price Statistics
The stock price has increased by -37.77% in the
last 52 weeks. The beta is 2.57, so Aeglea BioTherapeutics's
price volatility has been higher than the market average.
| Beta | 2.57 |
| 52-Week Price Change | -37.77% |
| 50-Day Moving Average | 13.75 |
| 200-Day Moving Average | 10.26 |
| Relative Strength Index (RSI) | 64.73 |
| Average Volume (20 Days) | 59,537 |
Income Statement
In the last 12 months, Aeglea BioTherapeutics had revenue of 2.33M
and earned -83.81M
in profits. Earnings per share was -24.86.
| Revenue | 2.33M |
| Gross Profit | 2.33M |
| Operating Income | -84.78M |
| Net Income | -83.81M |
| EBITDA | -84.78M |
| EBIT | -83.11M |
| Earnings Per Share (EPS) | -24.86 |
Full Income StatementBalance Sheet
The company has 34.86M in cash and 4.63M in
debt, giving a net cash position of 30.23M.
| Cash & Cash Equivalents | 34.86M |
| Total Debt | 4.63M |
| Net Cash | 30.23M |
| Retained Earnings | -425.62M |
| Total Assets | 207.26M |
| Working Capital | 161.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -80.14M
and capital expenditures -38K, giving a free cash flow of -80.18M.
| Operating Cash Flow | -80.14M |
| Capital Expenditures | -38K |
| Free Cash Flow | -80.18M |
| FCF Per Share | -23.78 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -3640.23% and -3598.75%.
| Gross Margin | 100% |
| Operating Margin | -3640.23% |
| Pretax Margin | -3604.59% |
| Profit Margin | -3598.75% |
| EBITDA Margin | -3640.23% |
| EBIT Margin | -3640.23% |
| FCF Margin | -3442.77% |
